Request a Proposal  

Welcome to Pharm-Olam Insights

Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.

Understanding-COVID-19_ebook_updated-0723-FINAL-1
Challenges to Research in the Age of COVID

The onset of the COVID-19 pandemic has introduced a variety of challenges to “business as usual.” The virus and the ensuing...


(3 minute read)

Tags: Pharm-Olam Insights, Infectious Disease & Vaccines, COVID-19

When Will Patients Return? The COVID Impact

Managing the COVID-19 pandemic has prompted countries and regions around the world to introduce a series of adaptions. For the...


(4 minute read)

Tags: Pharm-Olam Insights, Infectious Disease & Vaccines, COVID-19

The COVID 19 Map per ClinicalTrial Gov

The COVID Pandemic is continuing to evolve. Governments and companies around the world are striving to develop vaccines and...


(8 minute read)

Tags: Infectious Disease & Vaccines, COVID-19

Pharm-Olam Releases Updated Paper on the Impact of COVID on Clinical Research

Earlier this year, Pharm-Olam partnered with Informa’s Pharma Intelligence to draft a white paper that discusses the...


(1 minute read)

Tags: Infectious Disease & Vaccines, COVID-19, Global Coverage

6 Study Adaptations to Keep Studies Moving Despite COVID-19 Pandemic

The COVID-19 Pandemic continues to evolve and fluctuate across the globe – but not evenly or predictablySome countries have...


(22 minute read)

Tags: Pharm-Olam Insights, Infectious Disease & Vaccines, Investigator Insights,

Multicenter Phase III Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP)

Pharm-Olam was hired to support a Phase 3 study of a monoclonal antibody (mAb) and its impact on patients with...


(0 minute read)

Tags: Infectious Disease & Vaccines

Ethically Consenting Patients in Ventilator-Associated Studies

Pharm-Olam is experienced in dealing with ventilator-associated studies and consenting patients in an Intensive Care Unit...


(7 minute read)

Tags: Infectious Disease & Vaccines, COVID-19

Lessons Learned From a Phase II Influenza Clinical Trial

In this post, we discuss elements and lessons learned from a recent BARDA funded Influenza A Phase II study.  The study’s...


(3 minute read)

Tags: Pharm-Olam Insights, Infectious Disease & Vaccines

Join other Clinical Development experts to receive the latest industry news, trends and insights.

Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.

GDPR_Checklist-cover